Unknown

Dataset Information

0

A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis.


ABSTRACT: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) with the majority of cases characterised by relapsing/remitting (RRMS) attacks of neurologic dysfunction followed by variable resolution. Improving clinical outcomes in RRMS requires both a better understanding of the immunological mechanisms driving recurrent demyelination and better means of predicting future disease course to facilitate early targeted therapy. Here, we apply hypothesis-generating network transcriptomics to CD8+ cells isolated from patients in RRMS, identifying a signature reflecting expansion of a subset of CD8+ natural killer cells (NK8+) associated with favourable outcome. NK8+ are capable of regulating CD4+ T cell activation and proliferation in vitro, with reduced expression of HLA-G binding inhibitory receptors and consequent reduced sensitivity to HLA-G-mediated suppression. We identify surrogate markers of the NK8+ signature in peripheral blood leucocytes and validate their association with clinical outcome in an independent cohort, suggesting their measurement may facilitate early, targeted therapy in RRMS.

SUBMITTER: McKinney EF 

PROVIDER: S-EPMC7840761 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A CD8<sup>+</sup> NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis.

McKinney Eoin F EF   Cuthbertson Iona I   Harris Kristina M KM   Smilek Dawn E DE   Connor Christopher C   Manferrari Giulia G   Carr Edward J EJ   Zamvil Scott S SS   Smith Kenneth G C KGC  

Nature communications 20210127 1


Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) with the majority of cases characterised by relapsing/remitting (RRMS) attacks of neurologic dysfunction followed by variable resolution. Improving clinical outcomes in RRMS requires both a better understanding of the immunological mechanisms driving recurrent demyelination and better means of predicting future disease course to facilitate early targeted therapy. Here, we apply hypothesis-generat  ...[more]

Similar Datasets

| S-EPMC5794695 | biostudies-other
2015-03-10 | GSE66573 | GEO
2015-03-10 | E-GEOD-66573 | biostudies-arrayexpress
| S-EPMC7296935 | biostudies-literature
| S-EPMC4473119 | biostudies-literature
| S-EPMC4403723 | biostudies-literature
| S-EPMC3699254 | biostudies-other
| S-EPMC4361497 | biostudies-literature
| S-EPMC3503813 | biostudies-literature
| S-EPMC3593763 | biostudies-literature